Literature DB >> 10581150

Identification and characterization of the phosphorylation sites of the guanylyl cyclase-linked natriuretic peptide receptors A and B.

L R Potter1, T Hunter.   

Abstract

The binding of atrial natriuretic peptide and C-type natriuretic peptide to the guanylyl cyclase-linked natriuretic peptide receptors A and B (NPR-A and NPR-B), respectively, results in decreases in extracellular volume, vascular tension and cell proliferation. Both NPR-A and NPR-B are extensively phosphorylated in resting cells and receptor dephosphorylation is correlated with ligand-induced homologous desensitization. To understand the role of phosphorylation in the regulation of these receptors, we identified the in vivo phosphorylation sites of NPR-A and NPR-B and found that the phosphorylation of multiple sites within their kinase homology domains is absolutely required for their activation. In this review, we give a detailed description of the phosphopeptide mapping techniques that were used to identify and characterize these sites and discuss the potential pitfalls that are associated with them. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581150     DOI: 10.1006/meth.1999.0893

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  18 in total

Review 1.  Evolution of the membrane guanylate cyclase transduction system.

Authors:  Rameshwar K Sharma
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

2.  Mass spectrometric identification of phosphorylation sites in guanylyl cyclase A and B.

Authors:  Andrea R Yoder; Matthew D Stone; Timothy J Griffin; Lincoln R Potter
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

Review 3.  Atrial natriuretic factor-receptor guanylate cyclase signal transduction mechanism.

Authors:  Teresa Duda
Journal:  Mol Cell Biochem       Date:  2009-11-26       Impact factor: 3.396

Review 4.  Membrane guanylate cyclase is a beautiful signal transduction machine: overview.

Authors:  Rameshwar K Sharma
Journal:  Mol Cell Biochem       Date:  2009-12-03       Impact factor: 3.396

5.  Allosteric modification, the primary ATP activation mechanism of atrial natriuretic factor receptor guanylate cyclase.

Authors:  Teresa Duda; Prem Yadav; Rameshwar K Sharma
Journal:  Biochemistry       Date:  2011-01-26       Impact factor: 3.162

6.  GREBP, a cGMP-response element-binding protein repressing the transcription of natriuretic peptide receptor 1 (NPR1/GCA).

Authors:  Guy Martel; Pavel Hamet; Johanne Tremblay
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

7.  Further defining the clinical and molecular spectrum of acromesomelic dysplasia type maroteaux: a Turkish tertiary center experience.

Authors:  Pelin Ozlem Simsek-Kiper; Gizem Urel-Demir; Ekim Z Taskiran; Umut Ece Arslan; Banu Nur; Ercan Mihci; Mithat Haliloglu; Yasemin Alanay; Gulen Eda Utine; Koray Boduroglu
Journal:  J Hum Genet       Date:  2020-12-07       Impact factor: 3.172

8.  Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern.

Authors:  Juliane Schröter; René P Zahedi; Michael Hartmann; Birgit Gassner; Alexandra Gazinski; Jens Waschke; Albert Sickmann; Michaela Kuhn
Journal:  FEBS J       Date:  2010-04-26       Impact factor: 5.542

9.  Csk mediates G-protein-coupled lysophosphatidic acid receptor-induced inhibition of membrane-bound guanylyl cyclase activity.

Authors:  K S Madhusoodanan; Dagang Guo; Deirdre K McGarrigle; Thomas Maack; Xin-Yun Huang
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

10.  Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux.

Authors:  Alistair N Hume; Jens Buttgereit; Aydah M Al-Awadhi; Sarah S Al-Suwaidi; Anne John; Michael Bader; Miguel C Seabra; Lihadh Al-Gazali; Bassam R Ali
Journal:  Hum Mol Genet       Date:  2008-10-22       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.